China most likely to approve BioNTech’s Covid19 vaccine
China is planning to authorize the COVID-19 vaccine developed by Germany’s BioNTech SE by July. If approved, it would become the first foreign COVID-19 vaccine to be authorized in the country.
Chinese officials are reviewing clinical-trial data for the vaccine and are expected to authorize it for domestic use within the next 10 weeks.
The German drugmaker announced a potential deal with Shanghai Fosun Pharmaceutical Group Co Ltd in August to supply 10 million doses of their Covid-19 vaccine to Hong Kong and Macau.
The vaccine, developed in collaboration with Pfizer Inc, is already approved in several countries, including the United States, the United Kingdom and Israel.
Most of China’s shot makers cite trial data showing that their vaccines are close to 100% effective in preventing Covid-19 infections serious enough to require hospitalization when fully administered. But some Chinese public-health experts, including the head of China’s Center for Disease Control and Prevention, have pushed for the introduction of Western vaccines that are better at preventing mild infections.